FIGURE 5.

PtGR-1 is responsible for nitroalkene reduction in purified liver fractions. A, shown is dose-dependent inhibition of NO₂-OA (10 μm) reduction by 10 μg/ml PtGR-1-purified fraction in the presence of 15-oxo-PGE₂. Data are the means ± S.D. n = 3. Dose-dependent inhibition by 15-oxo-PGE₂ is statistically significant as determined by two-way ANOVA and the Bonferroni post-test (*, p < 0.01 versus control). B, shown is the effect of indomethacin (Indo) and dithionitrobenzoate (DTNB) on both NO₂-OA and 15-oxo-PGE₂ reduction by 7.5 μg/ml enzyme-purified fraction after a 10-min incubation. * and #, p < 0.0001 versus respective ethanol vehicle control (EtOH) by one-way ANOVA and Bonferroni post-test. Data are the means ± S.D. n = 3. C, shown is concomitant loss of NO₂-OA and 15-oxo-PGE₂ reductase activities upon PtGR-1 immunoprecipitation from a solution of enzyme-purified fraction containing ∼1 μg of PtGR-1. Data are the means ±S.D. n = 3. Inhibition is significant for both OA-NO₂ and 15-oxo-PGE₂ reduction as determined by two way ANOVA and Bonferroni post-test versus non-immunodepleted controls. * and #, p < 0.0001.